English version of Japanese guidance for the use of oral Janus kinase ( <scp>JAK</scp> ) inhibitors in the treatments of atopic dermatitis-Reference-Cited by-同舟云学术

English version of Japanese guidance for the use of oral Janus kinase ( JAK ) inhibitors in the treatments of atopic dermatitis

Published:2022-11-22 Issue:1 Volume:50 Page:
ISSN:0385-2407
Container-title:The Journal of Dermatology
language:en
Short-container-title:The Journal of Dermatology

Author:

Saeki Hidehisa¹^ORCID,Akiyama Masashi²^ORCID,Abe Masatoshi³,Igarashi Atsuyuki⁴^ORCID,Imafuku Shinichi⁵^ORCID,Ohya Yukihiro⁶,Katoh Norito⁷^ORCID,Kameda Hideto⁸,Kabashima Kenji⁹,Tsunemi Yuichiro¹⁰,Hide Michihiro¹¹¹²^ORCID,Ohtsuki Mamitaro¹³,

Affiliation:

1. Department of Dermatology Nippon Medical School Tokyo Japan

2. Department of Dermatology Nagoya University Graduate School of Medicine Nagoya Japan

3. Sapporo Skin Clinic Sapporo Japan

4. Department of Dermatology NTT Medical Center Tokyo Tokyo Japan

5. Department of Dermatology, Faculty of Medicine Fukuoka University Fukuoka Japan

6. Allergy Center National Center for Child Health and Development Tokyo Japan

7. Department of Dermatology Kyoto Prefectural University of Medicine Graduate School of Medical Science Kyoto Japan

8. Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine Toho University Tokyo Japan

9. Department of Dermatology, Graduate School of Medicine Kyoto University Kyoto Japan

10. Department of Dermatology Saitama Medical University Saitama Japan

11. Department of Dermatology, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan

12. Department of Dermatology Hiroshima Citizens Hospital Hiroshima Japan

13. Department of Dermatology Jichi Medical University Shimotsuke Japan

Publisher

Wiley

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1346-8138.16635

Reference31 articles.

1. IL-31 Expression by Inflammatory Cells is Preferentially Elevated in Atopic Dermatitis

2. Interleukin-22: A likely target for treatment of autoimmune diseases

3. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies

4. Ministry of Health Labour and Welfare.Guidelines for promoting the optimal use of baricitinib (Brand name: 2‐mg Olumiant tablets 4‐mg Olumiant tablets) Atopic dermatitis. (December2020). Accessed June 20 2022.https://www.pmda.go.jp/files/000238112.pdf(In Japanese).

5. Ministry of Health Labour and Welfare.Guidelines for promoting the optimal use of upadacitinib hydrate (Brand name: 7.5‐mg Rinvoq tablets 15‐mg Rinvoq tablets 30‐mg Rinvoq tablets) Atopic dermatitis. (Revised November 2021). Accessed June 20 2022.https://www.pmda.go.jp/files/000243653.pdf(In Japanese).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient and family burden in pediatric atopic dermatitis and its treatment pattern in Japan;International Journal of Dermatology;2024-05-29

2. (S)-(-)-blebbistatin O-benzoate has the potential to improve atopic dermatitis symptoms in NC/Nga mice by upregulating epidermal barrier function and inhibiting type 2 alarmin cytokine induction;PLOS ONE;2024-05-07

3. Cost‐effectiveness analysis of abrocitinib compared with standard of care in adult moderate‐to‐severe atopic dermatitis in Japan;The Journal of Dermatology;2024-04-22

4. Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study;Dermatology and Therapy;2023-12-21

5. JAK-STAT pathway inhibitors in dermatology;Anais Brasileiros de Dermatologia;2023-09